| 1 |
Siegel R, Ma J, Zou ZH, et al. Cancer statistics, 2014 [J]. CA Cancer J Clin, 2014, 67(1): 9-29.
|
| 2 |
Lin QJ, Yang F, Jin C, et al. Current status and progress of pancreatic cancer in China [J]. World J Gastroenterol, 2015, 21(26): 7988-8003.
|
| 3 |
陈万青，孙可欣，郑荣寿, 等. 2014年中国分地区恶性肿瘤发病和死亡分析 [J]. 中国肿瘤, 2018, 27(1): 1-14.
|
| 4 |
Karlson BM, Ekbom A, Lindgren PG, et al. Abdominal US for diagnosis of pancreatic tumor: prospective cohort analysis [J]. Radiology, 1999, 213(1): 107-111.
|
| 5 |
Bronstein YL, Loyer EM, Kaur H, et al. Detection of small pancreatic tumors with multiphasic helical CT [J]. Am J Roentgenol, 2004, 182(3): 619-623.
|
| 6 |
卢祎，龚彪. 超声在胰腺癌诊断中的应用进展 [J]. 临床超声医学杂志, 2015, 17(2): 108-111.
|
| 7 |
Hidalgo M. Pancreatic cancer [J]. N Engl J Med, 2010, 362(17): 1605-1617.
|
| 8 |
Satoi S, Yamamoto H, Takai S, et al. Clinical impact of multidetector row computed tomography on patients with pancreatic cancer [J]. Pancreas, 2007, 34: 175.
|
| 9 |
Holzapfel K, Reiser-Erkan C, Fingerle AA, et al. Comparison of diffusion-weighted MR imaging and multidetector-row CT in the detection of liver metastases in patients operated for pancreatic cancer [J]. Abdom Imaging, 2011, 36(2): 179-184.
|
| 10 |
杨超，罗国培，刘辰, 等. 2018年胰腺癌研究及诊疗新进展 [J]. 中国癌症杂志, 2019, 29(1): 1-8.
|
| 11 |
Spadi R, Brusa F, Ponzetti A, et al. Current therapeutic strategies for advanced pancreatic cancer: a review for clinicians [J]. World J Clin Oncol, 2016, 7(1): 27-43.
|
| 12 |
Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer [J]. Ann Surg, 2015, 261(1): 12-17.
|
| 13 |
Suker M, Beumer BR, Sadot E, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis [J]. Lancet Oncol, 2016, 17(6): 801-810.
|
| 14 |
Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer [J]. N Engl J Med, 2011, 364(19): 1817-1825.
|
| 15 |
Blazer M, Wu C, Goldberg RM, et al. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas [J]. Ann Surg Oncol, 2015, 22(4): 1153-1159.
|
| 16 |
王志刚. 超声分子影像学研究进展 [J]. 中国医学影像技术, 2009, 25(6): 921-924.
|
| 17 |
李坤成，于春水. 分子影像学研究进展 [J]. 中国医疗设备, 2008, 23(1): 1-4.
|
| 18 |
England CG, Hernandez R, Eddine SB, et al. Molecular Imaging of Pancreatic Cancer with Antibodies [J]. Mol Pharm, 2016, 13(1): 8-24.
|
| 19 |
Zhou Z, Lu ZR. Molecular imaging of the tumor microenvironment [J]. Adv Drug Deliv Rev, 2017, 113: 24-48.
|
| 20 |
Izuishi K, Yamamoto Y, Sano T, et al. Impact of 18-fluorodeoxyglucose positron emission tomography on the management of pancreatic cancer [J]. J Gastrointest Surg, 2010, 14(7): 1151-1158.
|
| 21 |
Zhang Y, Yang J, Li H, et al. Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis [J]. Int J Clin Exp Med, 2015, 8(7): 11683.
|
| 22 |
Niu G, Murad YM, Gao H, et al. Molecular targeting of CEACAM6 using antibody probes of different sizes [J]. J Control Release, 2012, 161(1): 18-24.
|
| 23 |
Houghton JL, Zeglis BM, Abdel-Atti D, et al. Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer [J]. Proc Natl Acad Sci USA, 2015, 112(52): 15850-15855.
|
| 24 |
England CG, Kamkaew A, Im HJ, et al. ImmunoPET Imaging of Insulin-Like Growth Factor 1 Receptor in a Subcutaneous Mouse Model of Pancreatic Cancer [J]. Mol Pharm, 2016, 13(6): 1958-1966.
|
| 25 |
Zettlitz KA, Tsai WK, Knowles SM, et al. Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti-Prostate Stem Cell Antigen Cys-Diabody [J]. J Nucl Med, 2018, 59(9): 1398-1405.
|
| 26 |
Liu Z, Liu H, Ma T, et al. Integrinalpha(v)beta(6)-Targeted SPECT Imaging for Pancreatic Cancer Detection [J]. J Nucl Med, 2014, 55(6): 989-994.
|
| 27 |
van der Zee JA, van Eijck CH, Hop WC, et al. Angiogenesis: a prognostic determinant in pancreatic cancer? [J]. Eur J Cancer, 2011, 47(17): 2576-2584.
|
| 28 |
Chen H, Hwang JH. Ultrasound-targeted microbubble destruction for chemotherapeutic drug delivery to solid tumors [J]. J Ther Ultrasound, 2014, 1(1): 10.
|
| 29 |
Xing LX, Shi QS, Zheng KL, et al. Ultrasound-Mediated Microbubble Destruction (UMMD) Facilitates the Delivery of CA19-9 Targeted and Paclitaxel Loaded mPEG-PLGA-PLL Nanoparticles in Pancreatic Cancer [J]. Theranostics, 2016, 6(10): 1573-1587.
|
| 30 |
Ma J, Shen M, Xu CS, et al. Biodegradable double-targeted PTX-mPEG-PLGA nanoparticles for ultrasound contrast enhanced imaging and antitumor therapy in vitro [J]. Oncotarget, 2016, 7(48): 80008-80018.
|
| 31 |
Abou-Elkacem L, Wang H, Chowdhury SM, et al. Thy1-Targeted Microbubbles for Ultrasound Molecular Imaging of Pancreatic Ductal Adenocarcinoma [J]. Clin Cancer Res, 2018, 24(7): 1574-1585.
|
| 32 |
Toma A, Otsuji E, Kuriu Y, et al. Monoclonal antibody A7-superparamagnetic iron oxide as contrast agent of MR imaging of rectal carcinoma [J]. Br J Cancer, 2005, 93: 131-136.
|
| 33 |
Zhou H, Qian W, Uckun FM, et al. IGF-1 receptor targeted nanoparticles for image-guided therapy of stroma-rich and drug resistant human cancer [J]. Proc SPIE Int Soc Opt Eng, 2016, 9836.
|
| 34 |
Wang L, Barth CW, Sibrian-Vazquez M, et al. Far-Red and Near-Infrared Seminaphthofluorophores for Targeted Pancreatic Cancer Imaging [J]. Acs Omega, 2017, 2(1): 154-163.
|
| 35 |
Chen X, Zhou H, Li XH, et al. Plectin-1 Targeted Dual-modality Nanoparticles for Pancreatic Cancer Imaging [J]. E Bio Medicine, 2018, 30: 129-137.
|